Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 14, 1998

View Archived Issues

Antiallergic efficacy of dual-action compound demonstrated in preclinical models

Company Profile: Athersys

Novel AIDS therapy shows promise

Atrix receives CE mark approval for Atrisorb; ISO 9001 certification granted

Nastech licenses nasal scopolamine to Schwarz

Eisai in-licenses antiobesity drug for Japanese market

Photofrin enters phase III testing for new indication

New use approved for Lescol

U.S. marketing application submitted for AD-32

PDE IV/TNF production inhibitors claimed by Schering AG for MS

Novartis discloses HIV protease inhibitors with excellent pharmacodynamic profile

Vertex describes new IMPDH inhibitors

Serotonergic agents prepared at Merck KGaA as potential antidepressants/anxiolytics

Merck & Co. describes new thrombin inhibitors

Novel ET antagonists claimed by BASF

Agents with affinity for 5-HT2 receptors under development at Janssen

Takeda obtains remaining HMR stake in French joint venture

Abgenix and Pfizer collaborate on XenoMouse antibodies

AHC-52, a new dihydropyridine with cardioprotective effects

Pharmacological profile of parenteral ET antagonist for SAH described by Roche

Preclinical and preliminary clinical results reported for CS-834

IC-351 advances to phase II for MED

DuPont Merck, Signal collaborate on HCV and HIV research

Abbott in-licenses lipid-lowering drug from Fournier

Korean researchers discover new PLC and PI turnover inhibitor from fungal strain

Indian researchers describe new anticancer agent

Carbapenems with enhanced antipseudomonal activity and stability

Genzyme Transgenics breakthrough could lead to potential malaria vaccine

IMPDH inhibitor VX-497 advances to clinical trials

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026